U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2007
239
Substance Class Protein
Created
by admin
on Wed Apr 02 07:48:16 GMT 2025
Edited
by admin
on Wed Apr 02 07:48:16 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG2
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
A3ULP0F556
Record Status Validated (UNII)
Record Version
  • Download
Related Record Type
Name Type Language
ALEXION
Preferred Name English
ECULIZUMAB
EMA EPAR   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
H5G11
Code English
H5G1.1VHC+H5G1.1VLC
Code English
ECULIZUMAB [USAN]
Common Name English
ECULIZUMAB [JAN]
Common Name English
ELIZARIA
Brand Name English
eculizumab [INN]
Common Name English
ECULIZUMAB [VANDF]
Common Name English
H5G1-1
Code English
IMMUNOGLOBULIN, ANTI-(HUMAN COMPLEMENT C5 .ALPHA.-CHAIN) (HUMAN-MOUSE MONOCLONAL 5G1.1 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 5G.1.1 LIGHT CHAIN, DIMER
Systematic Name English
ECULIZUMAB [EMA EPAR]
Common Name English
ECULIZUMAB [PURPLE BOOK CDER]
Common Name English
ECULIZUMAB [MI]
Common Name English
ECULIZUMAB [MART.]
Common Name English
SOLIRIS
Brand Name English
Eculizumab [WHO-DD]
Common Name English
5G1.1
Code English
H5G1.1
Code English
Classification Tree Code System Code
NCI_THESAURUS C20401
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 138800
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 434214
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 539416
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
NDF-RT N0000175974
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 398713
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
NDF-RT N0000175575
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 136100
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
EMA ASSESSMENT REPORTS SOLIRIS (AUTHORIZED: HEMOGLOBINURIA, PAROXYSMAL)
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 902222
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 173203
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
WHO-VATC QL04AA25
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 417213
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 279509
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
WHO-ATC L04AA25
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
FDA ORPHAN DRUG 354511
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
EU-Orphan Drug EU/3/14/1238
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
Code System Code Type Description
INN
8231
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
LACTMED
Eculizumab
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
IUPHAR
6884
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
SMS_ID
100000089131
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
NCI_THESAURUS
C48386
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
CAS
2648435-91-8
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
CAS
219685-50-4
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
NO STRUCTURE GIVEN
DAILYMED
A3ULP0F556
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
FDA UNII
A3ULP0F556
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
MESH
C481642
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
DRUG BANK
DB01257
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
CAS
2276801-68-2
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
ALTERNATIVE
USAN
LL-70
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201828
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
DRUG CENTRAL
4969
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
WIKIPEDIA
ECULIZUMAB
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
RXCUI
591781
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY RxNorm
EVMPD
SUB25187
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY
MERCK INDEX
m4823
Created by admin on Wed Apr 02 07:48:16 GMT 2025 , Edited by admin on Wed Apr 02 07:48:16 GMT 2025
PRIMARY Merck Index
From To
1_22 1_96
1_136 3_214
1_149 1_205
1_228 2_228
1_231 2_231
1_262 1_322
1_368 1_426
2_22 2_96
2_136 4_214
2_149 2_205
2_262 2_322
2_368 2_426
3_23 3_88
3_134 3_194
4_23 4_88
4_134 4_194
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_298
N 2_298
Related Record Type Details
Eculizumab-AEEB
SUB_CONCEPT->SUBSTANCE
Eculizumab-AEEB
BIOSIMILAR -> PARENT
Eculizumab-AAGH
SUB_CONCEPT->SUBSTANCE
COMPLEMENT C5
TARGET -> INHIBITOR
Related Record Type Details
ECULIZUMAB
ACTIVE MOIETY

Structural Modifications

Modification Type Location Site Location Type Residue Modified Extent Fragment Name Fragment Approval
AMINO ACID SUBSTITUTION [1_1] [2_1] PIDOLIC ACID SZB83O1W42
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Molecular Formula CHEMICAL
MOL_WEIGHT:ESTIMATED CHEMICAL
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966